Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss before noncontrolling interest	$ (3,982)	$ (9,960)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Loss (gain) on disposal of property and equipment, net		(12)
Depreciation expense	8	42
Share-based compensation expense	281	963
Change in fair value of warrants, related party	(921)	25
Amortization of debt discount	185	275
Changes in assets and liabilities:
Accounts receivable		7,790
Prepaid expenses and other assets	1,337	(2,072)
Long-term deposits		2,256
Accounts payable and accrued expenses	(1,445)	(2,605)
Deferred revenue	(913)	(2,064)
Other liabilities		(35)
Net cash used in operating activities	(5,450)	(5,397)
Cash flows from investing activities:
Proceeds from sale of assets		12
Net cash provided by investing activities		12
Cash flows from financing activities:
Proceeds from issuance of Class A Common Stock to a related party under the Letter Agreements	6,000
Proceeds from issuance of Class A Common Stock, net of offering costs	5,443
Repayment of notes payable	(2,717)
Net cash provided by financing activities	8,726
Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents	3,276	(5,385)
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period	4,183	14,420
Total cash, cash equivalents and restricted cash and cash equivalents, end of period	7,459	9,035
Non-cash activities:
Change in redemption value of noncontrolling interest	15,549	3,884
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock		151
Redeemable Noncontrolling Interest [Member]
Non-cash activities:
Change in redemption value of noncontrolling interest	$ (15,549)	$ (3,884)